Clinical Trial Update: Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating encorafenib and binimetinib, with or without nivolumab, for metastatic radioiodine-refractory BRAF V600-mutant …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Radioiodine-refractory Differentiated Thyroid Cancer

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• MEKTOVI (BINIMETINIB)
• OPDIVO (nivolumab)

Snippet

Sponsor: Providence Health & Services | Conditions: BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present | Phase 2 | Status: ACTIVE_NOT_RECRUITING